Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Treatment for Glioma: Retrospect and Prospect
share announcement

Treatment for Glioma: Retrospect and Prospect

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Neuro-Oncology".

Deadline for manuscript submissions: closed (15 March 2025) | Viewed by 22511

Special Issue Editors

Dr. Andrea Landi

E-Mail Website
Guest Editor
Associate Professor, Academic Neurosurgery, Department of Neuroscience, University of Padova, 35128 Padova, Italy
Interests: neurosurgery; neuro-oncology; functional neurosurgery
Dr. Valentina Baro

E-Mail Website
Guest Editor
Academic Neurosurgery, Department of Neuroscience, University of Padova, 35128 Padova, Italy
Interests: neurosurgeon; neurosurgical oncology; paediatric neurosurgery
Prof. Dr. Giuseppe Lombardi

E-Mail Website
Guest Editor
Department of Oncology, Oncology 1, Veneto Institute of Oncology-IRCCS, 35128 Padua, Italy
Interests: neuro-oncology; glioblastoma; gliomas; targeted therapy; brain tumors; immunotherapy; quality of life
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gliomas are the most common malignant primary brain tumor in adults. Generally, gliomas are divided into circumscribed and diffuse types, with the former being benign and curable after complete surgical resection and almost exclusively affecting children, and the latter being more malignant and unable to be cured following surgical resection alone. Despite growing knowledge of the molecular changes responsible for tumor development, gliomas remain neoplasms with unmet medical needs. Until very recently, the gold standard treatment for gliomas was surgical resection followed by radiotherapy plus temozolomide, according to the STUPP protocol. It is noteworthy that molecular alterations could represent important prognostic factors and specific targets for precision medicine trials in primary and recurrent gliomas. In the last few years, many translational and clinical studies have been performed, and new treatments with targeted therapy, such as precision medicine, immunotherapy, and their combination, are ongoing.

This Special Issue will cover all aspects of primary and recurrent gliomas, including original research on advanced imaging, molecular characteristics, current and experimental treatment options, supportive care, neurocognitive functions, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Dr. Andrea Landi
Dr. Valentina Baro
Prof. Dr. Giuseppe Lombardi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurosurgery
  • gliomas
  • new diagnostic strategies
  • preoperative planning
  • new surgical treatment choices
  • non-invasive therapies
  • new oncologic treatments

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 1226 KiB  
Article
Safety and Efficacy in the Transcortical and Transsylvian Approach in Insular High-Grade Gliomas: A Comparative Series of 58 Patients
by Alberto Morello, Francesca Rizzo, Andrea Gatto, Flavio Panico, Andrea Bianconi, Giulia Chiari, Daniele Armocida, Stefania Greco Crasto, Antonio Melcarne, Francesco Zenga, Roberta Rudà, Giovanni Morana, Diego Garbossa and Fabio Cofano
Curr. Oncol. 2025, 32(2), 98; https://doi.org/10.3390/curroncol32020098 - 10 Feb 2025
Viewed by 784
Abstract
Gliomas within the insular region represent one of the most challenging problems in neurosurgical oncology. There are two main surgical approaches to address the complex vascular network and functional areas around the insula: the transsylvian approach and the transcortical approach. In the literature, [...] Read more.
Gliomas within the insular region represent one of the most challenging problems in neurosurgical oncology. There are two main surgical approaches to address the complex vascular network and functional areas around the insula: the transsylvian approach and the transcortical approach. In the literature, there is not a clear consensus on the best approach in terms of safety and efficacy. The purpose of this study is to evaluate the effectiveness of these approaches and to analyze prognostic factors on the natural history of insular gliomas. Patients with newly diagnosed high-grade insular gliomas who underwent surgery between January 2019 and June 2024 were analyzed. The series was analyzed according to the classification of Berger–Sanai and Yaşargil. The Karnofsky performance score (KPS), extent of resection (EOR), progression-free survival (PFS), and overall survival (OS) were considered the outcome measures. A total of 58 primary high-grade insular glioma patients were enrolled in this study. The IDH mutation was found in 13/58 (22.4%); specifically, 3/13 (23.1%) were grade 4, and 10/13 (76.9%) were grade 3. Furthermore, 40/58 patients (69%) underwent gross total resection (GTR), 15 patients (26%) subtotal resection, and 3 patients (5%) partial resection. Middle cerebral artery encasement negatively affected the OS. GTR, radiotherapy, KPS, and autonomous deambulation at a month after surgery positively affected the OS. The surgical approach used was transsylvian and transcortical in 11 and 47 cases, respectively. The comparison between the two different approaches did not display differences in terms of neurological deficits and OS (p > 0.05). The transcortical approach was related to the greater achievement of GTR (p = 0.031). According to the Berger–Sanai classification, the transcortical approach has higher EOR and postoperative KPS when the lesion is in zone III-IV (p = 0.029). Greater resection of insular gliomas can be achieved with an acceptable morbidity profile and is predictive of improved OS. Both the transsylvian and transcortical corridors to the insula are associated with low morbidity profiles. The transcortical approach with intraoperative mapping is more favorable for achieving greater EOR, particularly in gliomas within the inferior border of the Sylvian fissure. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Figure 1

16 pages, 1901 KiB  
Article
Health-Related Quality of Life and Treatment Satisfaction of Patients with Malignant IDH Wild-Type Gliomas and Their Caregivers
by Anna Fischl, Michael Gerken, Patricia Lindberg-Scharf, Tareq M. Haedenkamp, Katharina Rosengarth, Andrea Hillberg, Martin Vogelhuber, Ingrid Schön, Martin Proescholdt, Tommaso Araceli, Michael Koller, Anne Herrmann, Oliver Kölbl, Tobias Pukrop, Markus J. Riemenschneider, Nils Ole Schmidt, Monika Klinkhammer-Schalke, Ralf Linker, Peter Hau and Elisabeth Bumes
Curr. Oncol. 2024, 31(10), 6155-6170; https://doi.org/10.3390/curroncol31100459 - 14 Oct 2024
Viewed by 1410
Abstract
(1) Background: Clinical aspects like sex, age, Karnofsky Performance Scale (KPS) and psychosocial distress can affect the health-related quality of life (HR-QoL) and treatment satisfaction of patients with malignant isocitrate dehydrogenase wild-type (IDHwt) gliomas and caregivers. (2) Methods: We prospectively investigated the HR-QoL [...] Read more.
(1) Background: Clinical aspects like sex, age, Karnofsky Performance Scale (KPS) and psychosocial distress can affect the health-related quality of life (HR-QoL) and treatment satisfaction of patients with malignant isocitrate dehydrogenase wild-type (IDHwt) gliomas and caregivers. (2) Methods: We prospectively investigated the HR-QoL and patient/caregiver treatment satisfaction in a cross-sectional study with univariable and multiple regression analyses. Questionnaires were applied to investigate the HR-QoL (EORTC QLQ-C30, QLQ-BN20) and treatment satisfaction (EORTC PATSAT-C33). (3) Results: A cohort of 61 patients was investigated. A higher KPS was significantly associated with a better HR-QoL regarding the functional scales of the EORTC QLQ-C30 (p < 0.004) and a lower symptom burden regarding the EORTC QLQ-BN20 (p < 0.001). The patient treatment satisfaction was significantly poorer in the patients older than 60 years in the domain of family involvement (p = 0.010). None of the investigated aspects showed a significant impact on the treatment satisfaction of caregivers. (4) Conclusions: We demonstrated that in patients with IDHwt gliomas, the KPS was the most important predictor for a better HR-QoL in functional domains. Data on the HR-QoL and treatment satisfaction in patients with IDHwt gliomas and their caregivers are rare; therefore, further efforts should be made to improve supportive care in this highly distressed cohort. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

16 pages, 1008 KiB  
Review
Glioblastoma in NF1: A Unique Entity—A Literature Review Focusing on Surgical Implication and Our Experience
by Elisa Garbin, Lorenzo Nicolè, Salima Magrini, Yuri Ceccaroni, Luca Denaro, Luca Basaldella and Marta Rossetto
Curr. Oncol. 2025, 32(4), 242; https://doi.org/10.3390/curroncol32040242 - 21 Apr 2025
Viewed by 180
Abstract
Glioblastoma in patients affected by NF1 germline mutation (NF1-associated GBM) represents a unique heterogeneous clinical and pathological entity. We have reviewed the few cases reported in the literature and they seem to have a better response to standard therapy and overall survival than [...] Read more.
Glioblastoma in patients affected by NF1 germline mutation (NF1-associated GBM) represents a unique heterogeneous clinical and pathological entity. We have reviewed the few cases reported in the literature and they seem to have a better response to standard therapy and overall survival than GBM in the non-NF1 population. We present two cases of long-survival NF1 patients with GBM. Case 1 was a 38-year-old woman with cerebellar GBM who underwent surgical asportation and the Stupp protocol many times with an overall survival of 117 months. Case 2 was a 47-year-old woman with GBM in the eloquent area of the right frontal lobe; she underwent surgical asportation and the Stupp protocol with an overall survival of 25 months. The data analysis demonstrates that NF1-associated GBM patients could be considered long-term survivors. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Figure 1

9 pages, 1116 KiB  
Review
Cutting Through History: The Evolution of Glioblastoma Surgery
by Abdullah H. Ishaque and Sunit Das
Curr. Oncol. 2024, 31(11), 6568-6576; https://doi.org/10.3390/curroncol31110485 - 24 Oct 2024
Cited by 1 | Viewed by 1657
Abstract
Despite significant advancements in neuro-oncology, management of glioblastoma remains a formidable challenge. Over the last century, the role and goals of surgery for patients with glioblastoma have evolved dramatically, with surgical intervention maintaining a central role in patient care. To understand the future [...] Read more.
Despite significant advancements in neuro-oncology, management of glioblastoma remains a formidable challenge. Over the last century, the role and goals of surgery for patients with glioblastoma have evolved dramatically, with surgical intervention maintaining a central role in patient care. To understand the future role of surgery in the management of glioblastoma, we must review and appreciate the historical journey that has led us to this juncture. Here, we provide an overview of this evolution and speak about anticipated changes in the future. “Certainly we cannot hope to solve the glioblastoma problem by throwing up our hands and saying there is nothing we can do. On the contrary, the solution lies in our constantly pressing on, making more and more strenuous efforts to remove these tumors, and not allowing ourselves to be deterred by any obstacles that lie in our path.”—Ernest Sachs, 1950. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Figure 1

9 pages, 528 KiB  
Review
Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
by Marcin Jezierzański, Natalia Nafalska, Małgorzata Stopyra, Tomasz Furgoł, Michał Miciak, Jacek Kabut and Iwona Gisterek-Grocholska
Curr. Oncol. 2024, 31(7), 3994-4002; https://doi.org/10.3390/curroncol31070296 - 12 Jul 2024
Cited by 28 | Viewed by 10313
Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive primary tumors of the central nervous system. It is associated with a very poor prognosis, with up to half of patients failing to survive the first year after diagnosis. It develops from glial tissue [...] Read more.
Glioblastoma multiforme (GBM) is one of the most aggressive primary tumors of the central nervous system. It is associated with a very poor prognosis, with up to half of patients failing to survive the first year after diagnosis. It develops from glial tissue and belongs to the adult-type diffuse glioma group according to the WHO classification of 2021. Therapy for patients with GBM is currently based on surgical resection, radiation therapy, and chemotherapy, but despite many efforts, there has been minimal progress in tumor management. The most important chemotherapeutic agent in the treatment of this tumor is temozolomide (TMZ), a dacarbazine derivative that presents alkylating activity. It is usually administered to patients concurrently with radiation therapy after surgical resection of the tumor, which is defined as the Stupp protocol. Temozolomide demonstrates relatively good efficacy in therapy, but it could also present with several side effects. The resistance of GBM to the drug is currently the subject of work by specialists in the field of oncology, and its use in various regimens and patient groups may bring therapeutic benefits in the future. The aim of this review paper is to summarize the relevance of TMZ in the treatment of GBM based on recent reports. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Figure 1

16 pages, 5100 KiB  
Review
An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma
by Thomas Joyce, Sarisha Jagasia, Erdal Tasci, Kevin Camphausen and Andra Valentina Krauze
Curr. Oncol. 2023, 30(9), 8278-8293; https://doi.org/10.3390/curroncol30090601 - 7 Sep 2023
Cited by 12 | Viewed by 4234
Abstract
Biomarkers for resistance in Glioblastoma multiforme (GBM) are lacking, and progress in the clinic has been slow to arrive. CD133 (prominin-1) is a membrane-bound glycoprotein on the surface of cancer stem cells (CSCs) that has been associated with poor prognosis, therapy resistance, and [...] Read more.
Biomarkers for resistance in Glioblastoma multiforme (GBM) are lacking, and progress in the clinic has been slow to arrive. CD133 (prominin-1) is a membrane-bound glycoprotein on the surface of cancer stem cells (CSCs) that has been associated with poor prognosis, therapy resistance, and tumor recurrence in GBM. Due to its connection to CSCs, to which tumor resistance and recurrence have been partially attributed in GBM, there is a growing field of research revolving around the potential role of CD133 in each of these processes. However, despite encouraging results in vitro and in vivo, the biological interplay of CD133 with these components is still unclear, causing a lack of clinical application. In parallel, omic data from biospecimens that include CD133 are beginning to emerge, increasing the importance of understanding CD133 for the effective use of these highly dimensional data sets. Given the significant mechanistic overlap, prioritization of the most robust findings is necessary to optimize the transition of CD133 to clinical applications using patient-derived biospecimens. As a result, this review aims to compile and analyze the current research regarding CD133 as a functional unit in GBM, exploring its connections to prognosis, the tumor microenvironment, tumor resistance, and tumor recurrence. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

14 pages, 1579 KiB  
Systematic Review
Surgical Management of Adult Brainstem Gliomas: A Systematic Review and Meta-Analysis
by Tamara Ius, Giuseppe Lombardi, Cinzia Baiano, Jacopo Berardinelli, Andrea Romano, Nicola Montemurro, Luigi Maria Cavallo, Francesco Pasqualetti and Alberto Feletti
Curr. Oncol. 2023, 30(11), 9772-9785; https://doi.org/10.3390/curroncol30110709 - 7 Nov 2023
Cited by 6 | Viewed by 3387
Abstract
The present review aims to investigate the survival and functional outcomes in adult high-grade brainstem gliomas (BGSs) by comparing data from resective surgery and biopsy. MEDLINE, EMBASE and Cochrane Library were screened to conduct a systematic review of the literature, according to the [...] Read more.
The present review aims to investigate the survival and functional outcomes in adult high-grade brainstem gliomas (BGSs) by comparing data from resective surgery and biopsy. MEDLINE, EMBASE and Cochrane Library were screened to conduct a systematic review of the literature, according to the PRISMA statement. Analysis was limited to articles including patients older than 18 years of age and those published from 1990 to September 2022. Case reports, review articles, meta-analyses, abstracts, reports of aggregated data, and reports on multimodal therapy where surgery was not the primary treatment were excluded. The ROBINS-I tool was applied to evaluate the risk of bias. Six studies were ultimately considered for the meta-analysis. The resective group was composed of 213 subjects and the bioptic group comprised 125. The analysis demonstrated a survival benefit in those patients in which an extensive resection was possible (STR HR 0.59 (95% CI 0.42, 0.82)) (GTR HR 0.63 (95% CI 0.43, 0.92)). Although surgical resection is associated with increased survival, the significantly higher complication rate makes it difficult to recommend surgery instead of biopsy for BSGs. Future investigations combining volumetric data and molecular profiles could add important data to better define the proper indication between resection and biopsy. Full article
(This article belongs to the Special Issue Treatment for Glioma: Retrospect and Prospect)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop